Argentum Pharmaceuticals Wins Patent Invalidation Trial Against Patent on Valeant's JUBLIA®

22:51 EDT 7 Jun 2018 | BioMedReports - Blog

On May 12, 2017, Argentum filed an inter partesreview (IPR) petition challenging all claims (claims 1 and 2) of the '506 patent. 

In

More From BioPortfolio on "Argentum Pharmaceuticals Wins Patent Invalidation Trial Against Patent on Valeant's JUBLIA®"